Epizyme Elects Kenneth Bate To Board Of Directors
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that Kenneth Bate, an independent consultant in the biotechnology industry, has been elected to the Company’s board of directors.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.